Cite
HARVARD Citation
Mills, A. et al. (2013). Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens. HIV clinical trials. 14 (5), pp. 216-223. [Online].